These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 15248226)

  • 1. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
    Mease PJ; Kivitz AJ; Burch FX; Siegel EL; Cohen SB; Ory P; Salonen D; Rubenstein J; Sharp JT; Tsuji W
    Arthritis Rheum; 2004 Jul; 50(7):2264-72. PubMed ID: 15248226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.
    Mease PJ; Kivitz AJ; Burch FX; Siegel EL; Cohen SB; Ory P; Salonen D; Rubenstein J; Sharp JT; Dunn M; Tsuji W
    J Rheumatol; 2006 Apr; 33(4):712-21. PubMed ID: 16463435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
    Sterry W; Ortonne JP; Kirkham B; Brocq O; Robertson D; Pedersen RD; Estojak J; Molta CT; Freundlich B
    BMJ; 2010 Feb; 340():c147. PubMed ID: 20124563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
    Mease PJ; Goffe BS; Metz J; VanderStoep A; Finck B; Burge DJ
    Lancet; 2000 Jul; 356(9227):385-90. PubMed ID: 10972371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
    Paul C; Solignac M
    Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
    de Vlam K; Lories RJ
    Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR; Keating GM
    Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept.
    Mease P
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S116-21. PubMed ID: 12463460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
    Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
    Mease PJ; Woolley JM; Singh A; Tsuji W; Dunn M; Chiou CF
    J Rheumatol; 2010 Jun; 37(6):1221-7. PubMed ID: 20395648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis.
    Puig L; Strohal R; Husni ME; Tsai TF; Noppakun N; Szumski A; Yang S; Robertson D; Boggs R; Koenig AS
    J Dermatolog Treat; 2015 Feb; 26(1):7-15. PubMed ID: 24283931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept: an evolving role in psoriasis and psoriatic arthritis.
    Prodanovich S; Ricotti C; Glick BP; Inverardi L; Leonardi CL; Kerdel F
    Am J Clin Dermatol; 2010; 11 Suppl 1():3-9. PubMed ID: 20586498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment.
    Boggs RL; Kárpáti S; Li W; Williams T; Pedersen R; Mallbris L; Gniadecki R
    BMC Dermatol; 2014 Aug; 14():14. PubMed ID: 25091090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.
    Gniadecki R; Robertson D; Molta CT; Freundlich B; Pedersen R; Li W; Boggs R; Zbrozek AS
    J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1436-43. PubMed ID: 22035157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
    Mease PJ
    Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.